United States-based Purdue Pharma has finalised major oncology related investments.
It was reported yesterday that the company has taken this step as part of its move to diversify its scientific research into areas of high unmet medical requirement. Through these investments, executed over a multi-year period and capped recently in 2017, the company is establishing a range of drug candidates with the potential to deliver new cancer therapies to patients within the next five years.
In assembling this portfolio, the company has four drug candidates in development for multiple cancer types that includes EDO-S7.1, a novel topoisomerase inhibitor; EDO-S101, a novel, first-in-class alkylating deacetylase inhibitor and EDO-B776 and EDO-B278, two late pre-clinical stage antibody-drug conjugates. Research on these drug candidates is being directed on behalf of Purdue by Mundipharma EDO GmbH, part of the Mundipharma network of independent associated companies.
TiumBio files Clinical Trial Application to start Phase 1b TU7710 study
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Scancell initiates SCOPE trial's iSCIB1+ cohort
Valneva launches Phase 1 trial for next-generation Zika vaccine
argenx obtains VYVGART approval for primary immune thrombocytopenia in Japan
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval